Cutaneous basal cell carcinoma
Jump to navigation
Jump to search
Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.
Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.
6 regimens on this page
7 variants on this page
|
Basal cell carcinoma
Cisplatin (Platinol) & Bleomycin (Blenoxane)
| back to top |
Regimen
Level of Evidence: Pilot, <20 patients reported
Neoadjuvant case reports only.
- Cisplatin (Platinol) 20 mg/m2 IV once per day on days 1 to 4
- Bleomycin (Blenoxane) 20 mg IV once per day on days 1 to 4
21-day cycles x 3 cycles
References
- Denic S. Preoperative treatment of advanced skin carcinoma with cisplatin and bleomycin. Am J Clin Oncol. 1999 Feb;22(1):32-4. link to original article contains protocol PubMed
Cisplatin (Platinol) & Doxorubicin (Adriamycin)
| back to top |
Regimen
Level of Evidence: Non-randomized
- Cisplatin (Platinol) 75 mg/m2 IV on day 1
- Doxorubicin (Adriamycin) 50 mg/m2 IV on day 1
21-day cycles
References
- Guthrie TH, Porubsky ES. Successful systemic chemotherapy of advanced squamous and basal cell carcinoma of the skin with cis-diamminedichloroplatinum III and doxorubicin. Laryngoscope. 1982 Nov;92(11):1298-9. PubMed
- Guthrie TH Jr, McElveen LJ, Porubsky ES, Harmon JD. Cisplatin and doxorubicin. An effective chemotherapy combination in the treatment of advanced basal cell and squamous carcinoma of the skin. Cancer. 1985 Apr 15;55(8):1629-32. PubMed
- Guthrie TH Jr, Porubsky ES, Luxenberg MN, Shah KJ, Wurtz KL, Watson PR. Cisplatin-based chemotherapy in advanced basal and squamous cell carcinomas of the skin: results in 28 patients including 13 patients receiving multimodality therapy. J Clin Oncol. 1990 Feb;8(2):342-6. link to original article contains verified protocol PubMed
Cisplatin (Platinol) & Paclitaxel (Taxol)
| back to top |
Regimen
Level of Evidence: Pilot, <20 patients reported
Case report only.
- Cisplatin (Platinol) 75 mg/m2 IV on day 1
- Paclitaxel (Taxol) 135 mg/m2 IV over 3 hours on day 1
21-day cycles
References
- Jefford M, Kiffer JD, Somers G, Daniel FJ, Davis ID. Metastatic basal cell carcinoma: rapid symptomatic response to cisplatin and paclitaxel. ANZ J Surg. 2004 Aug;74(8):704-5. link to original article contains verified protocol PubMed
Sonidegib (Odomzo)
| back to top |
Regimen, Migden et al. 2015 (BOLT)
Level of Evidence: Phase II
In Migden et al. 2015 (BOLT), Sonidegib 200 mg was assessed as having a better benefit-to-risk profile than the other tested dose, Sonidegib 800 mg.
- Sonidegib (Odomzo) 200 mg PO daily
given until progression of disease or unacceptable toxicity
References
- Migden MR, Guminski A, Gutzmer R, Dirix L, Lewis KD, Combemale P, Herd RM, Kudchadkar R, Trefzer U, Gogov S, Pallaud C, Yi T, Mone M, Kaatz M, Loquai C, Stratigos AJ, Schulze HJ, Plummer R, Chang AL, Cornélis F, Lear JT, Sellami D, Dummer R. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol. 2015 Jun;16(6):716-28. link to original article contains verified protocol PubMed
Vismodegib (Erivedge)
| back to top |
Regimen
Level of Evidence: Non-randomized
- Vismodegib (Erivedge) 150 mg PO daily
References
- Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Mackey HM, Lum BL, Darbonne WC, Marsters JC Jr, de Sauvage FJ, Low JA. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med. 2009 Sep 17;361(12):1164-72. Epub 2009 Sep 2. link to original article contains verified protocol PubMed
- LoRusso PM, Rudin CM, Reddy JC, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Chang I, Darbonne WC, Graham RA, Zerivitz KL, Low JA, Von Hoff DD. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res. 2011 Apr 15;17(8):2502-11. Epub 2011 Feb 7. link to original article contains verified protocol PubMed
Squamous cell carcinoma
Cetuximab (Erbitux)
| back to top |
Regimen #1, Maubec et al. 2011
Level of Evidence: Phase II
- Cetuximab (Erbitux) 400 mg/m2 IV x 1, then 250 mg/m2 IV once per week
given for at least 6 weeks, to be continued until progression of disease or unacceptable toxicity
Regimen #2, Kim et al. 2011
Level of Evidence: Pilot, <20 patients reported
Case report only.
- Cetuximab (Erbitux) 400 mg/m2 IV x 1, then 250 mg/m2 IV once per week x 3 months
Regimen #3, Miller et al. 2010
Level of Evidence: Pilot, <20 patients reported
Case report only.
- Cetuximab (Erbitux) 400 mg/m2 IV on day 1, then 250 mg/m2 IV on days 8, 15, 22
6-month cycles, given indefinitely unless progression occurs
References
- Bauman JE, Eaton KD, Martins RG. Treatment of recurrent squamous cell carcinoma of the skin with cetuximab. Arch Dermatol. 2007 Jul;143(7):889-92. link to original article PubMed
- Suen JK, Bressler L, Shord SS, Warso M, Villano JL. Cutaneous squamous cell carcinoma responding serially to single-agent cetuximab. Anticancer Drugs. 2007 Aug;18(7):827-9. link to original article PubMed
- Arnold AW, Bruckner-Tuderman L, Zuger C, Itin PH. Cetuximab therapy of metastasizing cutaneous squamous cell carcinoma in a patient with severe recessive dystrophic epidermolysis bullosa. Dermatology. 2009;219(1):80-3. Epub 2009 May 13. link to original article PubMed
- Miller K, Sherman W, Ratner D. Complete clinical response to cetuximab in a patient with metastatic cutaneous squamous cell carcinoma. Dermatol Surg. 2010 Dec;36(12):2069-74. doi: 10.1111/j.1524-4725.2010.01786.x. Epub 2010 Oct 11. link to original article contains verified protocol PubMed content property of HemOnc.org
- Kim S, Eleff M, Nicolaou N. Cetuximab as primary treatment for cutaneous squamous cell carcinoma to the neck. Head Neck. 2011 Feb;33(2):286-8. doi: 10.1002/hed.21299. link to original article contains verified protocol PubMed
- Maubec E, Petrow P, Scheer-Senyarich I, Duvillard P, Lacroix L, Gelly J, Certain A, Duval X, Crickx B, Buffard V, Basset-Seguin N, Saez P, Duval-Modeste AB, Adamski H, Mansard S, Grange F, Dompmartin A, Faivre S, Mentré F, Avril MF. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol. 2011 Sep 1;29(25):3419-26. Epub 2011 Aug 1. link to original article contains verified protocol PubMed
Cisplatin (Platinol) & Bleomycin (Blenoxane)
| back to top |
Regimen
Level of Evidence: Pilot, <20 patients reported
Neoadjuvant case reports only.
- Cisplatin (Platinol) 20 mg/m2 IV once per day on days 1 to 4
- Bleomycin (Blenoxane) 20 mg IV once per day on days 1 to 4
21-day cycles x 3 cycles
References
- Denic S. Preoperative treatment of advanced skin carcinoma with cisplatin and bleomycin. Am J Clin Oncol. 1999 Feb;22(1):32-4. link to original article contains protocol PubMed
Cisplatin (Platinol) & Doxorubicin (Adriamycin)
| back to top |
Regimen
Level of Evidence: Non-randomized
- Cisplatin (Platinol) 75 mg/m2 IV on day 1
- Doxorubicin (Adriamycin) 50 mg/m2 IV on day 1
21-day cycles
References
- Guthrie TH, Porubsky ES. Successful systemic chemotherapy of advanced squamous and basal cell carcinoma of the skin with cis-diamminedichloroplatinum III and doxorubicin. Laryngoscope. 1982 Nov;92(11):1298-9. PubMed
- Guthrie TH Jr, McElveen LJ, Porubsky ES, Harmon JD. Cisplatin and doxorubicin. An effective chemotherapy combination in the treatment of advanced basal cell and squamous carcinoma of the skin. Cancer. 1985 Apr 15;55(8):1629-32. PubMed
- Guthrie TH Jr, Porubsky ES, Luxenberg MN, Shah KJ, Wurtz KL, Watson PR. Cisplatin-based chemotherapy in advanced basal and squamous cell carcinomas of the skin: results in 28 patients including 13 patients receiving multimodality therapy. J Clin Oncol. 1990 Feb;8(2):342-6. link to original article contains verified protocol PubMed
Interferon alfa-2a (Roferon-A), Isotretinoin, Cisplatin (Platinol)
| back to top |
Regimen
Level of Evidence: Phase II
Note: Shin et al. 2002 did not clearly specify whether the interferon alfa used in the trial was 2a or 2b, but based on the details in the paper and the references cited, it is inferred that interferon alfa-2a was used.
- Interferon alfa-2a (Roferon-A) 5,000,000 units/m2 SC 3 times per week
- Isotretinoin (Accutane) 1 mg/kg PO daily
- Cisplatin (Platinol) 20 mg/m2 IV once per week
References
- Shin DM, Glisson BS, Khuri FR, Clifford JL, Clayman G, Benner SE, Forastiere AA, Ginsberg L, Liu D, Lee JJ, Myers J, Goepfert H, Lotan R, Hong WK, Lippman SM. Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer. J Clin Oncol. 2002 Jan 15;20(2):364-70. link to original article contains verified protocol PubMed